Implantation of Endobronchial Valves Versus Intrabronchial Valves in Patients With Severe Heterogeneous Emphysema

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

Patients with advanced heterogeneous emphysema experience improvement in clinical outcomes in the same way following either implantation of endobronchial valves or intrabronchial valves.

Condition or disease	Intervention/treatment	Phase
Pulmonary Emphysema	Device: EBV implantation; Device: IBV implantation	Phase 2; Phase 3

Detailed Description:

Patient enrollment and data acquisition is to be carried out on a prospective basis. It is planned to enroll a total of 50 patients with advanced heterogeneous emphysema. After decision to undertake endoscopic lung volume reduction by valve implantation patients will be randomised to two treatment arms. 25 patients receive unilateral IBV treatment or unilateral EBV treatment in each case. All patients will undergo treatment at one study centre in Heidelberg.

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	50 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Endoscopic Lung Volume Reduction by Implantation of Endobronchial Valves (EBV) vs. Intrabronchial Valves (IBV) in Patients With Severe Heterogeneous Emphysema
Study Start Date :	August 2011
Estimated Primary Completion Date :	May 2012
Estimated Study Completion Date :	May 2012

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Active Comparator: Endobronchial valves (EBV); Complete occlusion of one emphysematous destroyed lobe by implantation of endobronchial valves	Device: EBV implantation; In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.; Other Name: (Zephyr EBV)
Active Comparator: Intrabronchial valves (IBV); Complete occlusion of one emphysematous destroyed lobe by implantation of intrabronchial valves	Device: IBV implantation; In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.; Other Name: (Spiration IBV)

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Improvement in pulmonary function (FEV1 and RV/TLC) [ Time Frame: 6 months ]

Secondary Outcome Measures :

1. Number of severe adverse events [ Time Frame: 6 months ]
2. Evaluation of valve migration rate [ Time Frame: 6 months ]
3. Average changes in pulmonary function (FEV1, IVC, RV, TLC, RV/TLC) [ Time Frame: 6 months ]
4. Average changes in 6-minute-walk-distance [ Time Frame: 6 months ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	30 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• pulmonary function: FEV1 < 45 %, RV > 150 %, TLC > 100 %
• heterogeneous emphysema

Exclusion Criteria:

• homogeneous emphysema
• significant bronchiectasis
• severe concomitant diseases
• pregnancy

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Contacts

Contact: Daniela Gompelmann, MD	+49(0)62213968087	daniela.gompelmann@thoraxklinik-heidelberg.de
Contact: Felix JF Herth, MD	+49(0)62213961200	felix.herth@thoraxklinik-heidelberg.de

Locations

Germany
Thoraxklinik Heidelberg	Recruiting
Heidelberg, Germany, 69126
Contact: Daniela Gompelmann, MD +49(0)62213968087 daniela.gompelmann@thoraxklinik-heidelberg.de
Principal Investigator: Daniela Gompelmann, MD

Sponsors and Collaborators

Heidelberg University

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Felix JF Herth, Professor MD, University of Heidelberg
ClinicalTrials.gov Identifier:	NCT01457833 History of Changes
Other Study ID Numbers:	Protokoll E1.0-23.05.2011
First Posted:	October 24, 2011
Last Update Posted:	October 24, 2011
Last Verified:	October 2011

Additional relevant MeSH terms:

Emphysema; Pulmonary Emphysema; Pathologic Processes; Pulmonary Disease, Chronic Obstructive	Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases